A leading pharmaceutical company with treatments for multiple rare diseases, including Hereditary Angioedema (HAE) and Gaucher Disease, desired a more effective way to identify and target eligible patients earlier in the disease cycle. Traditional methods of combing through medical and prescription claims data proved insufficient due to the latency tied to claims and the limited clinical and diagnostic detail they provide.

See how timelier and more granular data-driven insights enabled faster identification and targeting of potential rare disease patients and treating HCPs.

lab data analysis

Download the Case Study

Text-Only Version